38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results

R Grisham; D Giri; M Henson; A Iasonos; Q Zhou; A McDonnell; J Girshman; R O’Cearbhaill; D Zamarin; C Aghajanian

doi:10.1136/ijgc-2019-IGCS.38

Article info

PDF

Plenary sessions

Plenary 6

IGCS19-0174

38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results

Free

Authors

R Grisham 1Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology, New York, USA PubMed articles Google scholar articles
D Giri 2Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, USA PubMed articles Google scholar articles
M Henson 3Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA PubMed articles Google scholar articles
A Iasonos 4Memorial Sloan Kettering Cancer Center, Department of Statistics, New York, USA PubMed articles Google scholar articles
Q Zhou 4Memorial Sloan Kettering Cancer Center, Department of Statistics, New York, USA PubMed articles Google scholar articles
A McDonnell 3Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA PubMed articles Google scholar articles
J Girshman 5Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, USA PubMed articles Google scholar articles
R O’Cearbhaill 3Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA PubMed articles Google scholar articles
D Zamarin 3Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA PubMed articles Google scholar articles
C Aghajanian 3Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA PubMed articles Google scholar articles

Citation

Grisham R, Giri D, Henson M, et al

38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results

International Journal of Gynecologic Cancer 2019;29:A23.

Publication history

First published September 18, 2019.

Online issue publication

September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password